Advitech announces stock options grant



    TSX VENTURE EXCHANGE: AVI

    QUEBEC CITY, July 31 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces that pursuant to the
Company's stock option plan, it has granted a total of 100,000 stock options
to Luc Clouâtre, Vice-President Business Development, Sales and Marketing of
Advitech. These options have an exercise price of $0.15 per share and may be
exercised during a period of five (5) years. This grant of options is subject
to appropriate regulatory approvals.

    ABOUT ADVITECH INC. www.advitech.com:

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has drawn up a research program to develop new applications
related to wound healing. This development is derived from both its XP-828L
and IM technological platforms.

    ABOUT DERMYLEX(R) www.dermylex.com:

    Dermylex(R), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(R) for that type of psoriasis. Dermylex(R) is currently available in
Canada and the U.S. (as BioDerm, Dermalyx(R)), as well as in France and
Belgium (as Psopax(R)).

    This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF




For further information:

For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
info@advitech.com; Serge Comeau, Investor's relations, (514) 862-4160,
s.comeau@advitech.com

Organization Profile

ADVITECH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890